Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)
Clicks: 236
ID: 120272
2000
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
65.9
/100
235 views
191 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Extended-spectrum beta-lactamase (ESBL)-producing organisms are a global problem. No randomized controlled trials have ever been performed to guide optimal treatment. However, in vitro studies and observational studies strongly suggest that carbapenems (imipenem or meropenem) should be regarded as d …
| Reference Key |
dl2000clinicalrecommendation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Paterson DL;; |
| Journal | clinical microbiology and infection : the official publication of the european society of clinical microbiology and infectious diseases |
| Year | 2000 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
anti-bacterial agents / therapeutic use*
beta-lactamases / metabolism*
d l paterson
enterobacteriaceae / growth & development
pmid:11168179
doi:10.1046/j.1469-0691.2000.00107.x
carbapenems / therapeutic use
cephalosporins / therapeutic use
enterobacteriaceae / enzymology*
enterobacteriaceae infections / drug therapy*
beta-lactamases / biosynthesis
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.